Distinct mechanisms of action of tumor necrosis factor antagonists: What are the clinical implications?

Seminars in Arthritis and Rheumatism

Volumn 34, Issue 5 SUPPL., 2005, Pages 1-2

  Rigby, William F C ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; CYTOKINE; ETANERCEPT; HYBRID PROTEIN; INFLIXIMAB; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY; PROTEIN P55; PROTEIN P75; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIBODY RESPONSE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; AUTOIMMUNITY; CANCER; CLINICAL TRIAL; CONFERENCE PAPER; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; EPSTEIN BARR VIRUS; GRANULOMATOSIS; HUMAN; IMMUNOGENICITY; INFECTION; INFLAMMATORY DISEASE; LAMINA PROPRIA; LYMPHOMA; MEDIATOR; MYCOBACTERIOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

EID: 17044380191     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2005.01.001     Document Type: Conference Paper

References (9)

1. P.S. Hench, E.C. Kendall, C.H. Slocumb Cortisone, its effects on rheumatoid arthritis, rheumatic fever, and certain other conditions Merck Rep 59 1950 9 14
2. M.E. Weinblatt, E.C. Keystone, D.E. Furst Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA Trial Arthritis Rheum 48 2003 35 45
3. L. Klareskog, D. van der Heijde, J.P. de Jager TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis double-blind randomised controlled trial Lancet 363 9410 2004 675 681 Feb 28
4. F.C. Breedveld, P. Emery, E. Keystone Infliximab in active early rheumatoid arthritis Ann Rheum Dis 63 2004 149 155
5. G. Kollias, E. Douni, G. Kassiotis On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease Immunol Rev 169 1999 175 194
6. B. Scallon, A. Cai, N. Solowski Binding and functional comparisons of two types of tumor necrosis factor antagonists J Pharmacol Exp Ther 301 2002 418 426
7. B.C. Chiu, D.D. Weisenburger An update of the epidemiology of non-Hodgkin's lymphoma Clin Lymphoma 4 2003 161 168
8. L. Georgescu, G.C. Quinn, S. Schwartzman Lymphoma in patients with rheumatoid arthritis association with the disease state or methotrexate treatment Semin Arthritis Rheum 26 1997 794 804
9. X. Mariette, D. Cazals-Hatem, J. Warszawki Lymphomas in rheumatoid arthritis patients treated with methotrexate a 3-year prospective study in France Blood 99 2002 3909 3915